IL-23 and PSMA targeted duo-CAR-Ts (IL-23mAb-T2A-PSMA) were more efficient in prostate cancer eradication than PSMA CARs only and induced stronger T cell activation, and increased cytokine production when compared to single-molecule tandem CAR IL-23mAb/PSMA (267). The gene discussed is FOLH1; the disease is prostate cancer.